Public Policy

In the next several months, the president and members of Congress will decide whether to continue the funding and authorities associated with Project BioShield, which seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear (CBRN) attacks.

The 2012 BIO International Convention featured a broad array of top-level speakers, addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 65 countries.

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.

Successful multi-sector global health programs engage partners and policymakers early, communicate openly and frequently with relevant stakeholders, and empower and involve communities, according to a website relaunched this week, Case Studies for Global Health.

John discusses the state of the industry and what he expects will be the top three issues highlighted at this year's BIO International Convention.  For more information on GEN, please visit http://www.genengnews.com/

William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth. Mr. Waddill provided testimony today on behalf of BIO at a Senate Committee on Banking, Housing, and Urban Affairs hearing.